Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tykerb Efficacy In Breast Cancer Not NICE Enough To Justify Price Tag, Says U.K. Agency

This article was originally published in The Pink Sheet Daily

Executive Summary

Interim analysis finds GSK's lapatinib and capecitabine combo therapy - at almost $50,000 annually - not cost-effective.
Advertisement

Related Content

U.K.'s Controversial NICE Suspends Publication Of Guidances Until After General Election
U.K.'s Controversial NICE Suspends Publication Of Guidances Until After General Election
EMEA Backs Conditional Marketing Of GSK’s Tykerb, Withdrawal Of Novartis’ Prexige In EU
EMEA Backs Conditional Marketing Of GSK’s Tykerb, Withdrawal Of Novartis’ Prexige In EU

Topics

Advertisement
UsernamePublicRestriction

Register

PS068185

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel